MICRO LABS has secured FDA approval for a generic substance pursuant to ANDA206371, a milestone expected to bolster the company's market share and expand its commercial footprint in the regulated therapeutic segment.
MICRO LABS has secured FDA approval for a generic substance pursuant to ANDA206371, a milestone expected to bolster the company's market share and expand its commercial footprint in the regulated therapeutic segment.